<DOC>
	<DOC>NCT00812045</DOC>
	<brief_summary>The purpose of this study is to determine the effect of AZD1236 in patients with cystic fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4 weeks.</brief_summary>
	<brief_title>Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Have a clinical diagnosis of cystic fibrosis with an FEV1 &gt;40% of predicted normal Be able to comply with induced sputum procedure postmenopausal surgically sterile female (total hysterectomy and /or bilateral total oophorectomy) Concomitant diagnosis of significant pulmonary disease other than CFrelated lung disease, including symptomatic asthma and allergic bronchopulmonary aspergillosis Treatment with any immunomodulatory agents within 8 weeks prior to Visit 2 Known to be infected with Burkholderia cepacia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Induced sputum</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>biomarker</keyword>
	<keyword>CYBER</keyword>
</DOC>